Bicycle Therapeutics (BCYC) Net Income towards Common Stockholders (2018 - 2026)

Bicycle Therapeutics has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$60.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders changed 0.12% year-over-year to -$60.8 million; the trailing twelve-month figure through Mar 2026 stood at -$219.0 million (down 7.78% YoY), and the FY2025 full-year result was -$219.0 million, down 29.54% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$60.8 million, down from -$20.2 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$20.2 million in Q4 2025, with the low at -$79.0 million in Q2 2025.
• Historically, Net Income towards Common Stockholders has averaged -$43.7 million across 5 years, with a median of -$42.6 million in 2023.
• The largest YoY upside for Net Income towards Common Stockholders was 61.13% in 2025 against a maximum downside of 128.72% in 2025.
• Bicycle Therapeutics' Net Income towards Common Stockholders stood at -$30.0 million in 2022, then slumped by 63.78% to -$49.1 million in 2023, then slipped by 5.61% to -$51.9 million in 2024, then soared by 61.13% to -$20.2 million in 2025, then tumbled by 201.8% to -$60.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$60.8 million (Q1 2026), -$20.2 million (Q4 2025), and -$59.1 million (Q3 2025), per Business Quant data.